DNTH Dianthus Therapeutics, Inc.
Price Chart
Executive Summary
Dianthus Therapeutics priced an upsized public offering of 7,313,582 shares at $81.00 per share and pre-funded warrants for 402,468 additional shares at $80.999, raising approximately $625 million in gross proceeds. The funds will support clinical development, commercial readiness, and general corporate purposes, with a 30-day underwriter option to purchase up to an additional 1,157,407 shares.
Key Financial Metrics
Actionable Insight
Monitor for underwriter option exercise within 30 days; assess dilution impact given new shares issued and pre-funded warrants outstanding. Evaluate use of proceeds against pipeline milestones to determine capital efficiency.
Key Facts
- Priced public offering of 7,313,582 common shares at $81.00 per share
- Pre-funded warrants issued for 402,468 shares at $80.999, exercisable immediately at $0.001 per share
- Total gross proceeds: ~$625 million (before expenses)
- Underwriters granted 30-day option to purchase up to 1,157,407 additional shares
- Proceeds to fund clinical and preclinical programs, commercial readiness, and general corporate use
- Offering expected to close on March 12, 2026, subject to customary conditions
Financial Impact
$625 million in gross proceeds, with potential for ~$93.8 million more if underwriters fully exercise option (1,157,407 shares × $81)
Risk Factors
- Significant near-term dilution from new shares and pre-funded warrants
- Proceeds dependent on biotech R&D success, which carries high clinical failure risk
- No guarantee that capital will lead to commercial or regulatory success
Market Snapshot
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3253481 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 12, 2026
1d ago
|
8-K
| $76.45 awaiting T+20 | awaiting T+20 | — | $82.07 (+7.35%) |
|
Jun 11, 2026
1d ago
|
Institutional Cluster
| $76.55 awaiting T+20 | awaiting T+20 | — | $82.07 (+7.21%) |
|
May 5, 2026
5w ago
|
8-K
| $90.42 $84.97 | ▼ −6.03% | ▼ −8.81% | $82.07 (−9.23%) |
|
Mar 12, 2026
13w ago
|
Press Release
| $77.86 $90.00 | ▲ +15.59% | ▲ +12.00% | $82.07 (+5.41%) |
|
Mar 12, 2026
13w ago
|
8-K
| $80.32 $89.77 | ▲ +11.77% | ▲ +9.79% | $82.07 (+2.18%) |
|
Mar 12, 2026
13w ago
|
Insider Cluster
| $80.32 $89.77 | ▼ −11.77% | ▼ −9.79% | $82.07 (−2.18%) |
|
Mar 12, 2026
13w ago
|
Insider Cluster
| $80.32 $89.77 | ▼ −11.77% | ▼ −9.79% | $82.07 (−2.18%) |
|
Mar 11, 2026
13w ago
|
Press Release
| $85.84 $91.66 | ▲ +6.78% | ▲ +6.26% | $82.07 (−4.39%) |
|
Mar 9, 2026
13w ago
|
Press Release
| $79.23 $86.20 | ▲ +8.80% | ▲ +11.60% | $82.07 (+3.58%) |
|
Mar 8, 2026
13w ago
|
Press Release
| $79.23 $86.20 | ▲ +8.80% | ▲ +11.60% | $82.07 (+3.58%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access